BACKGROUND: Treatment for @entity1 with @entity454 ( @entity454 ) and severe @entity472 ( @entity472 ) includes @entity2333 ( @entity2333 ), surgical (SAVR), or transcatheter (TAVR) aortic valve replacement. We compared outcomes among these strategies. METHODS: A retrospective review of @entity1 with @entity454 undergoing treatment for severe @entity472 between 07/2007 and 06/2015 was performed at our center. @entity1 were classified based on treatment: @entity2333 -only, TAVR, or SAVR. Baseline characteristics and 30-day outcomes were compared among groups. A 1-year survival analysis was performed. RESULTS: Of 85 @entity1 , 25 (29.4%) underwent @entity2333 , 30 (35.3%) TAVR, and 30 (35.3%) SAVR. @entity1 in the SAVR group, compared to the @entity2333 or TAVR @entity1 , were younger (63 vs. 74 vs. 71 years, P   =   0.02) and had less prior @entity64 (3.3% vs. 12.0% vs. 30.0%, P   =   0.008). While all @entity2333 @entity1 had NYHA class III/IV, 93.3% and 76.7% of @entity1 had NYHA class III/IV in the TAVR and SAVR group, respectively (P   =   0.001). @entity2333 @entity1 were less likely to have @entity955 than TAVR or SAVR @entity1 (16.0% vs. 43.3% vs. 50.0%, P   =   0.03). All @entity1 were high risk, but there was a statistical trend to lower STS scores in the SAVR group (8.6% vs. 13.5% vs. 13.5%, P   =   0.08). There was no significant difference in 30-day mortality (16.7% vs. 10.0% vs. 10.0%, P   =   0.74), but @entity2333 treated @entity1 had an increased 1-year mortality compared to those treated with TAVR or SAVR (87.0% vs. 32.0%, vs. 36.7%, P=<0.001). Independent predictors of 1-year mortality were a higher STS score (HR 1.026, 95%CI 1.002-1.051) and @entity2333 -only strategy ( @entity2333 vs. TAVR: HR 3.961, 95%CI 1.595-9.840), but dialysis duration and type, and SAVR versus TAVR were not. CONCLUSIONS: @entity1 with @entity454 and severe @entity472 have a similar and higher survival with TAVR or SAVR when compared to @entity2333 at 1-year. These results may influence @entity1 care decisions favoring valve replacement in @entity472 @entity1 with @entity454 .    2016 Wiley Periodicals, Inc.

@entity454 and severe XXXX : Does valve replacement improve one-year outcomes?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity2333 :: ('MESH:D001018', 'Disease') :: ['balloon aortic valvuloplasty', 'BAV'] @entity472 :: ('MESH:D001024', 'Disease') :: ['AS', 'aortic stenosis'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']
@entity472 :: (MESH:D001024,Disease) :: ['aortic stenosis']
